Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
October 30, 2018
Navicent Health Adopts iCAD’s Breast Cancer Detection and Therapy Solutions to Enhance Patient Care
NASHUA, N.H., and MACON, Ga., Oct. 30, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, ...
October 30, 2018
Mustang Bio Announces Updates on CAR T Cell Therapy Clinical Trials with City of Hope
NEW YORK, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a company focused on the development of novel immunotherapies based on proprietary ...
October 30, 2018
CymaBay Announces the Initiation of the Seladelpar Global Phase 3 Registration Study (ENHANCE) for the Treatment of Primary Biliary Cholangitis and Additional Corporate Updates
NEWARK, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), today announced that the company has initiated the seladelpar Phase 3 registration study ...
October 30, 2018
BioTime to Report Third Quarter 2018 Financial Results on November 8th, 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will report its third ...
October 30, 2018
STRATA Skin Sciences to Host 3rd Quarter 2018 Financial Results and Business Update Conference call on Tuesday, November 13, 2018
HORSHAM, Pa., Oct. 30, 2018 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to ...
October 30, 2018
FDA Grants Breakthrough Therapy Designation (BTD) for UroGen Pharma’s UGN-101 for the Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)
UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today ...
October 30, 2018
InspireMD to Report Third Quarter 2018 Financial Results and Provide Business Update on Tuesday, November 6
TEL AVIV, Israel, Oct. 30, 2018 (GLOBE NEWSWIRE) --  InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention ...
October 29, 2018
OncoCyte Completes Successful Transition to New Diagnostic Testing Platform and Initiates DetermaVu™ Development Studies
ALAMEDA, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, ...
October 29, 2018
OSE Immunotherapeutics Announces Publication in Nature Communications on Anti-IL-7 Receptor Antagonist (OSE-127)
NANTES, France, Oct. 29, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA(ISIN: FR0012127173; Mnémo: OSE) today announced publication in Nature Communications of its monoclonal antibody (OSE-127) targeting ...
October 29, 2018
Genkyotex Announces Positive Outcome from the Independent SMB’s Third Pre-Planned Review of the Phase 2 Trial of GKT831 in Primary Biliary Cholangitis
Genkyotex (GKTX.PA) (GKTX.PA) (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies (the “Company”), announces today that the ...
October 29, 2018
AC Immune Partner Life Molecular Imaging Presents New Clinical Study Results for Tau PET-Tracer 18F-PI-2620
Lausanne, Switzerland, October 29, 2018 - AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company focused on neurodegenerative diseases, today announced that its partner Life ...
October 29, 2018
AC Immune SA: New Data Supporting Crenezumab as Potential Alzheimer's Therapy
Lausanne, Switzerland, October 29, 2018   AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company focused on neurodegenerative diseases, today announced the presentation of in vitro data ...
October 29, 2018
RedHill Biopharma to Host Analyst and Investor Webcast on TALICIA® for H. pylori infection on October 30, 2018
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 29, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty ...
October 29, 2018
Prometic Announces Extension of Debt Maturities to 2024
LAVAL, QC , Oct. 29, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF)("Prometic" or the "Corporation") announced today that it has signed a binding letter ...
October 29, 2018
miRagen Therapeutics to Present at two Investor Conferences in November 2018
BOULDER, Colo., Oct. 29, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, ...
October 29, 2018
Athenex Announces FDA Allowance of Investigational New Drug Application of Eribulin ORA to Begin Clinical Trials
BUFFALO, N.Y., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies ...
October 29, 2018
ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals
LEIDEN, the Netherlands, Oct. 29, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR) a company dedicated to changing lives through the creation of transformative RNA ...
October 29, 2018
Foamix Pharmaceuticals Third Quarter Financial Results Conference Call & Webcast Scheduled for November 8
REHOVOT, Israel, and BRIDGEWATER, N.J., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing ...
October 29, 2018
BioTime Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced positive additional results from an ongoing Phase I/IIa ...
October 29, 2018
Opiant Pharmaceuticals Appoints Seasoned Pharmaceutical Executive Craig Collard to Board of Directors
SANTA MONICA, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug ...
Page 9 of 117